INT257301

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.30
First Reported 2008
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 5
Total Number 5
Disease Relevance 1.97
Pain Relevance 2.26

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (Pde5a) signal transduction (Pde5a)
Anatomy Link Frequency
smooth muscle 2
Pde5a (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Bioavailability 2 98.84 Very High Very High Very High
Spinal cord 2 93.40 High High
antinociception 23 92.64 High High
Analgesic 2 90.12 High High
Neuropathic pain 19 86.56 High High
Hyperalgesia 9 85.52 High High
allodynia 9 83.96 Quite High
Cold hyperalgesia 1 83.08 Quite High
Acute pain 6 78.04 Quite High
Pain 17 77.84 Quite High
Disease Link Frequency Relevance Heat
Neuropathic Pain 33 86.56 High High
Nociception 11 86.32 High High
Hyperalgesia 10 85.52 High High
Pain 22 78.04 Quite High
Disease 20 69.40 Quite High
Injury 5 68.92 Quite High
Myocardial Infarction 2 60.24 Quite High
Increased Venous Pressure Under Development 13 55.68 Quite High
Erectile Dysfunction 247 41.60 Quite Low
Pulmonary Disease 31 27.92 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
By inhibiting the breakdown of cGMP, PDE5 inhibitors create increased bioavailability of cGMP, which both facilitates and potentiates the NO-mediated relaxation of erectile smooth muscle with sexual stimulation.
Protein_catabolism (breakdown) of cGMP in smooth muscle associated with bioavailability
1) Confidence 0.30 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2643112 Disease Relevance 0.18 Pain Relevance 0.09
The cyclic nucleotide phosphodiesterase is responsible for degrading the second messenger nucleotides cAMP and cGMP.
Protein_catabolism (degrading) of cGMP
2) Confidence 0.28 Published 2008 Journal Journal of Korean Medical Science Section Body Doc Link PMC2610640 Disease Relevance 0.48 Pain Relevance 0.68
Guanylyl cyclase catalyzes the formation of cyclic guanosine monophosphate (cGMP) from GTP, leading to the synthesis of cGMP, whereas cGMP-specific phosphodiesterase catalyzes the hydrolysis of cGMP to GMP.2 Accordingly, intracellular cGMP concentrations are regulated by the action of guanylyl cyclase and the rate of degradation by cGMP-specific phosphodiesterase.6,7
Protein_catabolism (hydrolysis) of cGMP
3) Confidence 0.21 Published 2010 Journal Yonsei Medical Journal Section Body Doc Link PMC2799976 Disease Relevance 1.12 Pain Relevance 1.40
PDE1A and PDE1B preferentially hydrolyze cGMP, whereas PDE1C degrades both cAMP and cGMP with high affinity.
Protein_catabolism (degrades) of cGMP
4) Confidence 0.17 Published 2008 Journal International Journal of Chronic Obstructive Pulmonary Disease Section Body Doc Link PMC2650605 Disease Relevance 0 Pain Relevance 0
By inhibiting the breakdown of cGMP, PDE5 inhibitors create increased bioavailability of cGMP, which both facilitates and potentiates the NO-mediated relaxation of erectile smooth muscle with sexual stimulation.
Protein_catabolism (breakdown) of PDE5 in smooth muscle associated with bioavailability
5) Confidence 0.15 Published 2008 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2643112 Disease Relevance 0.18 Pain Relevance 0.09

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox